Tag: reimbursement

ISPOR’s 2nd PLENARY OF 18th ANNUAL EUROPEAN CONGRESS EXPLORES EVOLUTION OF OUTCOMES RESEARCH IN HEALTH CARE

PANEL EXAMINES OUTCOMES RESEARCH IN DAILY PRACTICE  Milan, Italy—November 10, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress second plenary session — Outcomes Research: Are We Ready to Put Theory into Practice? — was held

Posted in Announcements, ISPOR News & Press Tagged with: , , , , , , , , , ,

THE PROBLEM OF REIMBURSEMENT FOR SINGLE-USE DEVICES IN ASIA-PACIFIC COUNTRIES

Seoul, South Korea – In Asia-Pacific countries, as elsewhere, less than 6% of total health care spending per capita is on medical devices, though these technologies often make critical contributions to the delivery of clinical and economic benefits to both

Posted in ISPOR News & Press, Policy Perspectives, Value in Health Regional Issues Tagged with: , , ,

IDENTIFYING THE FACTORS THAT ENHANCE POSITIVE DRUG REIMBURSEMENT RECOMMENDATION IN SCOTLAND

Rotterdam, The Netherlands – Given limited health care resources and rising expenditures on pharmaceuticals, policy makers are increasingly confronted with the challenging task to improve patient outcomes and reimburse new pharmaceutical interventions. Arguably, Scotland is often one of the first

Posted in Announcements, Health Policy Analyses, Value in Health Tagged with: , , , , , ,

SUCCESS FEE: A NOVEL TOOL FOR THE SUSTAINABILITY OF NOVEL EXPENSIVE THERAPIES

Catania, Italy – To guarantee rapid patient access to high cost, innovative therapies, policy makers have introduced cost-containment strategies based on the partial or total reimbursements of a drug price. Under these agreements, market access for a drug is granted

Posted in Announcements, Policy Perspectives, Value in Health Tagged with: , , , , , , ,

How Does a Drug Get Reimbursed in Iran?

Rotterdam, the Netherlands & Tehran, Iran – Researchers at the Institute for Medical Technology Assessment sought out to examine and describe the Iranian decision-making process regarding drug reimbursement and the role of the main stakeholders in this process.

Posted in Value in Health Regional Issues Tagged with: , ,

A New Approach To Korea’s Reimbursement Coverage And Pricing Rules For Medical Devices Long Overdue

Seoul, South Korea – Since 1989, Korea has had a comprehensive National Health Insurance system, which also covers most implantable and disposable medical devices. Although medical devices account for only about 4% of the total budget, considerable attention is paid to

Posted in Policy Perspectives, Value in Health Tagged with: , , , , ,

Does an Official Positive List of Medical Devices Exist?

Istanbul, Turkey – Official positive list practices revealing the reimbursement status of medical devices globally has become a significant benchmark for decision makers. Considering this fact, it is crucial to explicate whether an official positive list of reimbursed medical devices exists

Posted in Health Policy Analyses, ISPOR CONNECTIONS, Value & Outcomes Spotlight Tagged with: , ,

Paying For Medicines Based On Health Outcomes

Princeton, NJ, USA – With the rising cost of new medicines, health care payers and providers are looking for the best bang for their buck – the most effective treatment at the lowest cost.  Payers (insurance companies, managed care organizations and

Posted in ISPOR News & Press, Value in Health Tagged with: , , , ,

What Are The Important Factors In Selecting TCM?

Shenyang, China & Newcastle, Australia – The use of traditional Chinese medicine (TCM) has been gaining momentum in the past decades internationally. Even with quite a sizeable consumption and expenditure, there are still many barriers that prevent TCM to be reimbursed

Posted in Value in Health Regional Issues Tagged with: , , ,